12:00 AM
Jan 16, 2012
 |  BC Week In Review  |  Company News  |  Other News

Sanofi, Seikagaku, Zimmer autoimmune news

The U.S. District Court for the District of Massachusetts granted a motion from Sanofi for a preliminary injunction preventing Seikagaku from selling its Gel-One at a price under $547.60, which is the market price of competitor product Synvisc-One from Sanofi's Genzyme Corp. subsidiary. The injunction will be in...

Read the full 227 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >